Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Dermata Therapeutics (Nasdaq: DRMA) reported a strategic shift toward direct-to-consumer skincare in Q1 2026, advancing its new Tome brand. The company plans to launch its once-weekly Tome Foundational Treatment in mid-2026 and is preparing a second DTC product.
Dermata raised $2.0 million in net proceeds via its ATM, ending March 31, 2026 with $6.9 million in cash and cash equivalents and expecting funding runway into Q1 2027. Q1 2026 research and development expenses declined to $0.4 million, while selling, general and administrative expenses rose to $1.5 million, reflecting marketing, audit, and legal costs.
Dermata (Nasdaq:DRMA) received notice of acceptance from the Australian Patent Office for Australian Patent Application No. 2020315876, covering topical delivery of dermal fillers using its Bioneedle Delivery System (BDS). The patent will be automatically issued three months after acceptance unless a third party files an opposition.
The acceptance would be Dermata's first patent, if issued, for BDS with dermal fillers and adds to existing allowed and issued BDS patents for botulinum toxin in the US, Australia, and Japan. The company noted a strategic shift to selling direct to skincare professionals.
Dermata Therapeutics (Nasdaq:DRMA) announced a strategic pivot to develop and commercialize direct-to-consumer skincare under the new brand Tome, planning to launch its first product, the Foundational Treatment, in mid-2026. The company reported year-end 2025 cash of $7.5 million and raised $15.4 million in gross proceeds during 2025 and early 2026, which it expects will fund operations into the first quarter of 2027. Dermata also noted a $5.3 million reduction in R&D spending versus 2024 following completion of the STAR-1 acne study and withdrew its IND for XYNGARI to focus on the DTC strategy.
Dermata (Nasdaq:DRMA) appointed Kyra Peckaitis as Vice President, Marketing to lead the launch of the new Tome skincare brand, with first commercial products expected in mid-2026. Ms. Peckaitis began March 9, 2026 and received a non-qualified option for 15,000 shares at an exercise price of $1.33 per share.
The option vests 25% after one year, then monthly over 36 months, and was granted outside the company’s shareholder-approved equity incentive plan as a board-approved inducement under Nasdaq Listing Rule 5635(c)(4).
Dermata (Nasdaq:DRMA) unveiled Tome, a consumer-facing skincare brand positioning itself as "skintech at home." The company plans to launch its first Tome product, an over-the-counter once-weekly acne and resurfacing treatment, in mid-2026. Tome is described as "Studied Skincare™," combining timeless natural ingredients with modern innovations and dermatologist study to deliver high-potency, prescription-like results without prescriptions.
The announcement frames this as a strategic shift toward direct-to-consumer products intended to become foundational in simple weekly routines for improving overall skin quality.
Dermata (NASDAQ:DRMA) announced the Australian Patent Office granted Australian Patent No. 2019419387 for its Spongilla technology combination as a method to treat acne on January 20, 2026. This follows an already-issued U.S. patent covering the same technology. Dermata plans to launch a once-weekly, over-the-counter acne treatment system incorporating Spongilla in mid-2026 in the U.S. The company said the granted patent strengthens its global intellectual property estate, with additional patent filings pending in other jurisdictions and Australia cited as a key future market.
Dermata Therapeutics (Nasdaq:DRMA / DRMAW) closed a private placement priced at-the-market, issuing 2,022,062 shares (or pre-funded warrants) and accompanying series C and series D warrants at $2.04 per share (or pre-funded warrant).
Gross proceeds were approximately $4.1 million upfront, with up to $8.3 million of additional gross proceeds possible if warrants are fully exercised. Series C warrants expire five years after stockholder approval; series D warrants expire 24 months after approval. The company amended prior warrants covering 120,734 shares, lowering the exercise price to $2.04. Insiders participated; H.C. Wainwright acted as placement agent. Proceeds are planned for general corporate purposes and product launch activities.
Dermata Therapeutics (NASDAQ:DRMA / DRMAW) announced a private placement to issue 2,022,062 shares (or pre-funded warrants) plus series C and short-term series D warrants at $2.04 per share, providing approximately $4.1 million of gross proceeds upfront and up to ~$8.3 million additional if warrants are fully exercised (total ~$12.4 million). Series C warrants expire five years; series D warrants expire 24 months; warrant exercises and amended warrants are subject to stockholder approval. Closing expected on or about December 29, 2025. Company insiders, including the CEO and CFO, are participating. H.C. Wainwright is placement agent. Net proceeds for general corporate purposes and OTC acne kit activities.
Dermata Therapeutics (NASDAQ:DRMA) announced it will unveil a new brand identity for its over-the-counter skincare business in the coming weeks, positioning the unit as a "science-first" consumer skincare brand that blends ancestral remedies with clinical innovation. The company said the identity reflects a mission to deliver potent, health-forward products and will frame therapies and technologies through quantifiable performance.
Dermata plans to launch its first OTC once-weekly acne kit in mid-2026 and will release visual assets, product positioning, and phased launch communications over the coming months.
Dermata Therapeutics (Nasdaq: DRMA) announced a strategic pivot to develop and commercialize over-the-counter dermatology products and reported Q3 2025 results. The company plans to launch a once-weekly acne kit using its Spongilla technology in mid-2026 and is developing branding, packaging, and manufacturing for direct-to-consumer and professional sales.
Recent clinical progress includes positive topline Phase 3 STAR-1 results that met all three primary endpoints and showed separation from placebo by week 4. As of September 30, 2025, Dermata had $4.7 million in cash and expects funding into Q2 2026.